Skip to main content
get in touch

Research Report · Feb 20, 2026

Insurance Claim Denial Management

Prepared: February 20, 2026 Data vintage: Primarily 2023-2025 sources (from analyst training data; live web verification was unavailable) Caveat: WebSearch and WebFetch tools were blocked during this session. All figures below are drawn from the analyst's training corpus (cut-off May 2025) and cite the original publication sources. Numbers should be independently verified before use in investment memos.

Author: Rigid Body Dynamics

1. PROBLEM MARKET SIZE

Revenue at Risk from Claim Denials

MetricValueSource
Total US hospital revenue billed to insurers (2024)~$1.5 trillionAHA Annual Survey / CMS NHE data
Initial denial rate (industry average)10-15% of all claims; up to 20-25% at some systemsHFMA 2023 "Denial Benchmarking" report; Experian Health 2024 survey
Revenue initially denied150B150B - 225B annuallyDerived from above
Net write-off from denials (after appeals)~1.5-3% of net patient revenueHFMA; Crowe RCA benchmarking
Estimated annual write-offs from denials20B20B - 45BDerived; aligns with KFF and Advisory Board estimates

Cost Hospitals Spend on Denial Management

MetricValueSource
Average cost to rework/appeal a single denied claim2525 - 118 per claim (varies by complexity)AAPC 2023; Change Healthcare 2024 Revenue Cycle Index
Estimated total industry spend on denial management (staff, appeals, outsourcing, write-offs combined)19.7B19.7B - 25B+Becker's Hospital Review 2023; derived from FTE and outsourcing data
Average hospital employs dedicated denial FTEs15-50 FTEs per mid-large hospital systemHFMA workforce surveys
Avg fully loaded cost per denial management FTE55,00055,000 - 75,000/yearBureau of Labor Statistics; Becker's

Bottom line: Denials put 150B225Bofhospitalrevenueatriskannually.Hospitalscollectivelyspend150B-225B of hospital revenue at risk annually. Hospitals collectively spend 20B+ fighting them, and still write off $20B-45B.


2. CURRENT SPEND TO MANAGE

Revenue Cycle Management (RCM) Software Market

MetricValueSource
2023 market size154B154B - 160B (includes services + software)Grand View Research 2024; Verified Market Research
2024 estimated~$176BGrand View Research
2030 forecast329B329B - 398BGrand View Research; Fortune Business Insights
CAGR (2024-2030)10.3% - 11.5%Multiple analyst firms

Note: The broader RCM market includes outsourced services, not just software. The software-only segment is a subset (~$20-25B in 2024).

Denial Management Software (Sub-Segment)

MetricValueSource
2023 estimated market size4.5B4.5B - 5.5BDerived from Grand View Research RCM segmentation
CAGR12-14%Market Research Future; Allied Market Research
2030 forecast10B10B - 13BProjected

Medical Billing Outsourcing Market

MetricValueSource
2023 market size13.5B13.5B - 14.8BPolaris Market Research; Grand View Research
CAGR (2024-2030)10.1% - 12.3%Multiple sources
2030 forecast26B26B - 30BProjected

3. COST OF INACTION

MetricValueSource
% of denied claims never appealed50-65%Premier Inc. 2023 analysis; Advisory Board 2024
Reason most not appealedCost-to-appeal exceeds claim value, or staff bandwidth exhaustedHFMA
Average cost to work one denial25(simple)to25 (simple) to 118 (complex/clinical)Change Healthcare 2024 Index; AAPC
Average cost to file a formal appeal4848 - 118 per claimAAPC; Experian Health
Revenue lost from uncontested denials annually10B10B - 27B (est. 50-65% of 20B20B-45B write-off pool)Derived
Appeal overturn/success rate (when pursued)50-70%MGMA 2023; HFMA

Key insight: More than half of denied claims are never contested, yet when hospitals do appeal, they win 50-70% of the time. This represents a massive recoverable revenue pool that is abandoned due to operational capacity constraints.


4. VOLUME FREQUENCY

MetricValueSource
Total medical claims submitted/year (US, all payers)~6 billion claims (professional + institutional combined)CAQH 2024 Index; CMS data
Hospital/facility claims specifically~1.2 - 1.5 billionAHA; derived from CMS
Initial denial rate (all claims)10-15%Experian Health 2024; Change Healthcare
Initial denial rate (hospital inpatient)15-25% (higher complexity)HFMA 2023; KFF
Claims denied on first submission annually~200-350 million hospital claimsDerived
Prior authorization denial rate (Medicare Advantage)13-18% of prior auth requestsKFF 2024 Medicare Advantage report; OIG
Appeals filed as % of denials35-50%Premier; Advisory Board
Estimated appeals filed annually (hospital)~70-175 millionDerived
Average time to resolve a denial (rework + appeal)30-60 days (simple); 90-180+ days (complex/multi-level appeal)HFMA; Waystar benchmarking data
Average days in A/R for denied claims45-90 days beyond initial billing cycleMGMA benchmarks

5. WHY STILL UNSOLVED

Despite billions invested in RCM technology, denial rates have risen ~23% over the past decade (Change Healthcare Index, 2024). Key structural reasons:

5.1 Payer Algorithm Changes (Moving Target Problem)

  • Insurers continuously update clinical criteria, coverage policies, and prior auth rules
  • Medicare Advantage plans use proprietary AI/ML algorithms to auto-adjudicate (and auto-deny) claims
  • OIG found MA plans denied 13-18% of prior auths, many of which met Medicare coverage criteria
  • Payer rule changes outpace provider RCM software update cycles

5.2 Coding Complexity Explosion

  • ICD-10 has ~72,000 diagnosis codes vs. ~14,000 in ICD-9
  • CPT code updates annually (300+ changes/year)
  • Modifier requirements increasingly complex
  • Clinical documentation must precisely match coding requirements

5.3 Staff Turnover and Workforce Crisis

  • Medical coder/biller turnover: 25-40% annually (AAPC 2024 salary survey)
  • Average time to train a denial management specialist: 6-12 months
  • Post-COVID burnout accelerated departures from revenue cycle roles
  • Experienced coders retiring faster than replacements entering

5.4 Data Fragmentation

  • Average hospital uses 15+ disparate systems (EHR, PM, clearinghouse, payer portals)
  • Lack of real-time eligibility/benefit verification at point of care
  • Clinical documentation lives in EHR; billing data in PM system; payer rules on external portals
  • No single source of truth connecting clinical, financial, and payer data

5.5 Misaligned Incentives

  • Payers benefit financially from denials (float, write-offs)
  • Payers face minimal penalties for inappropriate denials
  • Provider appeals process is deliberately cumbersome
  • CMS has been slow to enforce payer accountability

5.6 Legacy RCM Software Limitations

  • Most RCM platforms are rules-based, not predictive
  • Retrospective denial tracking vs. prospective denial prevention
  • Batch processing vs. real-time intervention
  • Limited NLP/AI capability for clinical documentation analysis

6. WILLINGNESS TO PAY SIGNALS

What Hospitals Pay Today

CategoryAnnual SpendSource
In-house RCM team (avg mid-size hospital, ~50 FTEs)3M3M - 5M/yearBLS; HFMA
In-house RCM team (large health system, 200+ FTEs)12M12M - 20M/yearBecker's
Outsourced RCM services (% of collections model)4-8% of net patient revenueHFMA; vendor benchmarks
Outsourced RCM for a $500M revenue hospital20M20M - 40M/yearDerived
Denial management software (per-provider pricing)50K50K - 500K/year per facilityVendor pricing; KLAS
AI-powered denial prevention platforms200K200K - 1M+/year per health systemKLAS 2024; vendor data

VC/PE Investment Activity (2023-2025)

Company / DealAmountDateInvestor(s)
Waystar IPO~$968M raised (IPO)June 2024Public markets (backed by EQT, CPPIB)
Akasa (AI for RCM)$60M Series B2023Andreessen Horowitz (a16z)
AKASA total raised$120M+Through 2024a16z, BOND, others
Olive AI (RCM automation)Wound down; assets acquired by Waystar, others2023Previously raised $900M+
Infinx (AI prior auth)$75M+ total2023-2024Multiple PE/VC
Apixio/ClaimLogiq (AI denials)Acquired by New Mountain Capital2023PE
R1 RCMAcquired by TowerBrook/CD&R for $8.9B2024PE
Ensemble Health PartnersAcquired by Bon Secours for strategic partnership2024Health system
Nividous / Autonomize AI$15-30M rounds for RCM AI startups2023-2024Various VC
Medallion (credentialing/RCM adjacent)$44M Series C2024Various

Signal strength: The R1 RCM acquisition at 8.9BandWaystarIPOat 8.9B and Waystar IPO at ~3.7B market cap on listing day demonstrate massive PE/public market appetite. Multiple AI-native startups raising 50M50M-120M rounds specifically for denial management signals strong WTP for next-gen solutions.


7. MARKET GROWTH RATE

Segment2024 Size (Est.)2030 ForecastCAGR
Total RCM Market (services + software)$176B329B329B - 398B10.3% - 11.5%
RCM Software Only20B20B - 25B48B48B - 55B11% - 13%
Denial Management Software5B5B - 6B10B10B - 13B12% - 14%
Medical Billing Outsourcing14B14B - 15B26B26B - 30B10% - 12%
AI in Healthcare RCM (sub-segment)2B2B - 3B8B8B - 12B20% - 25%

Key growth drivers:

  • Regulatory complexity increasing (No Surprises Act, prior auth reform)
  • Labor shortages forcing automation adoption
  • Medicare Advantage enrollment growth (more complex payer mix)
  • AI/ML maturation enabling predictive denial prevention
  • CMS interoperability mandates creating data availability

8. KEY PLAYERS TODAY

Major RCM / Denial Management Companies

CompanyEst. Revenue (2024)Segment FocusNotes
Waystar~770M770M-850MRCM software, clearinghouse, denial mgmtIPO June 2024; EQT-backed; acquired Olive AI assets
R1 RCM~$2.2BEnd-to-end RCM outsourcing + techAcquired by TowerBrook/CD&R for $8.9B (2024)
Cotiviti (Verscend)~1.0B1.0B-1.2BPayment accuracy, analytics, risk adjustmentOwned by Veritas Capital; serves payer + provider
Change Healthcare (Optum)~$3.5B+ (segment)Clearinghouse, RCM, payment integrityPart of UnitedHealth/Optum after $7.8B acquisition (2022); major cyberattack Feb 2024
nThrive (now part of R1 RCM)Folded into R1Coding, CDI, denial managementMerged with R1 RCM
Omega Healthcare~500M500M-700MRCM outsourcing (India-based operations)Large offshore BPO for RCM
Ensemble Health Partners~$1.0B+End-to-end RCM outsourcingStrategic deals with health systems
GeBBS Healthcare~200M200M-300MRCM outsourcing, codingIndia-based
AGS Health~150M150M-250MRCM outsourcing, denial managementIndia-based
Experian Health~500M500M-700M (health segment)Eligibility, claims, patient accessPart of Experian plc

AI-Native Disruptors

CompanyFunding / StageFocus
AKASA$120M+ raisedAI-powered RCM automation
Infinx$75M+ raisedAI prior authorization
Apixio / ClaimLogiqPE-backed (New Mountain)AI-powered denial management
Adonis~$20M+ raisedAI denial prevention for physician groups
Rhyme HealthEarly stageAI denial appeals automation
ValerEarly stageDenial prediction and prevention

9. KEY SOURCES

All sources referenced in this report. Note: URLs are provided as best-known links; some may require subscription access.

Industry Associations and Government

  1. HFMA (Healthcare Financial Management Association) - Denial benchmarking reports and workforce surveys
  2. KFF (Kaiser Family Foundation) - Medicare Advantage denial data
  3. CMS National Health Expenditure Data - Total healthcare spending
  4. OIG (HHS Office of Inspector General) - MA denial investigations
  5. AHA (American Hospital Association) - Hospital statistics
  6. CAQH Index - Claims volume and automation data

Market Research Firms

  1. Grand View Research - RCM market analysis
  2. Fortune Business Insights - RCM market forecast
  3. Polaris Market Research - Medical billing outsourcing
  4. Allied Market Research - Denial management market
  5. Market Research Future - Healthcare RCM

Industry Publications and Data

  1. Change Healthcare / Optum Revenue Cycle Index - Denial rate trends and cost-to-appeal data
  2. Experian Health - State of Claims survey (2024)
  3. Becker's Hospital Review - RCM workforce and spending
  4. Fierce Healthcare - Denial rate trends
  5. KLAS Research - RCM software vendor ratings
  6. Advisory Board (Optum) - Denial management analytics
  7. Premier Inc. - Denial analytics and benchmarking
  8. AAPC - Coding workforce and salary data
  9. MGMA - Practice management benchmarks

Deal / Investment Sources

  1. Waystar S-1 / IPO Filing - SEC Edgar
  2. R1 RCM Take-Private - Press coverage
  3. AKASA Funding - Crunchbase / press releases

EXECUTIVE SUMMARY

The US insurance claim denial management problem represents one of the largest inefficiencies in healthcare:

  • 150B150B-225B in hospital revenue is initially denied annually
  • 20B20B-45B is permanently written off, with 50-65% of denials never even appealed
  • When hospitals do appeal, they win 50-70% of the time -- revealing a massive recoverable revenue pool abandoned due to operational constraints
  • Hospitals spend $20B+ annually on denial management through a combination of in-house staff, outsourced services, and technology
  • The RCM market is growing at 10-13% CAGR with AI-specific sub-segments growing at 20-25%
  • PE/VC conviction is high: R1 RCM acquired for 8.9B,WaystarIPOat 8.9B**, **Waystar IPO at ~3.7B, and $200M+ deployed into AI-native denial management startups in 2023-2024

The problem persists because it is structurally adversarial (payers benefit from denials), operationally complex (72,000 ICD-10 codes, constantly changing payer rules), and plagued by workforce challenges (25-40% coder turnover). Legacy RCM tools are rules-based and retrospective. The market is ripe for AI-native solutions that can predict denials before submission, auto-generate appeals, and adapt in real-time to payer algorithm changes.

Largest opportunity vector: Converting the 50-65% of denials that are currently abandoned into appealed and recovered revenue using AI-powered automation. At a 60% appeal success rate, this represents 6B6B-16B in recoverable revenue annually -- a value proposition that can support premium SaaS pricing.